CN107460371B - A kind of Zn-Li system kirsite and the preparation method and application thereof - Google Patents
A kind of Zn-Li system kirsite and the preparation method and application thereof Download PDFInfo
- Publication number
- CN107460371B CN107460371B CN201610387456.7A CN201610387456A CN107460371B CN 107460371 B CN107460371 B CN 107460371B CN 201610387456 A CN201610387456 A CN 201610387456A CN 107460371 B CN107460371 B CN 107460371B
- Authority
- CN
- China
- Prior art keywords
- kirsite
- coating
- preparation
- film layer
- degradable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
- C22C—ALLOYS
- C22C18/00—Alloys based on zinc
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L17/00—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters
- A61L17/06—At least partially resorbable materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/04—Metals or alloys
- A61L27/047—Other specific metals or alloys not covered by A61L27/042 - A61L27/045 or A61L27/06
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/02—Inorganic materials
- A61L31/022—Metals or alloys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/148—Materials at least partially resorbable by the body
-
- C—CHEMISTRY; METALLURGY
- C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
- C22C—ALLOYS
- C22C1/00—Making non-ferrous alloys
- C22C1/02—Making non-ferrous alloys by melting
Abstract
The invention discloses a kind of Zn-Li system kirsites and the preparation method and application thereof.Zn-Li system of the present invention kirsite includes Zn and Li；By weight percentage, the mass percentage of Li is 0~30% in the kirsite, but does not include 0.Preparation method includes the following steps: that (1) mixes the Zn and Li, obtains mixture；(2) by the mixture according to following a) or b) step is handled, and is then cooled down to get the kirsite is arrived；A) in CO2And SF6Under atmosphere protection, the mixture is subjected to melting or sintering；B) under vacuum atmosphere protection, hydrogen is dissolved in the mixture and carries out the melting.Kirsite excellent in mechanical performance prepared by the present invention can provide permanently effective support force in vivo, have excellent cell compatibility, blood compatibility and tissue, organ compatibility, can be used for the preparation of biological and medicinal implant material.
Description
Technical field
The present invention relates to a kind of Zn-Li system kirsite and the preparation method and application thereof, belong to medical metal material preparation and
Technical field.
Background technique
Currently used for clinical bio-medical material mainly have biomedical metallic material, inorganic material, high molecular material,
Composite material and biomimetic material etc..Biomedical metallic material is the metal or alloy for being used as bio-medical material, this kind of material
It is the widest load implantation material of clinical application with high mechanical strength and anti-fatigue performance.Such material using non-
Often extensively, throughout various aspects such as sclerous tissues, soft tissue, artificial organs and shell auxiliary appliances.In addition to requiring this kind of material to have
Have outside good mechanical property and relevant physical property, excellent antibiosis reason corrosivity and biocompatibility are also that it must have
Standby condition.Main problem in medical metal material application be corrosion as physiological environment and caused by metal ion to week
The regression of tissue diffusion and implantation material self property is enclosed, the former may cause toxic side effect, and the latter frequently results in the mistake of implantation
It loses.Having been used to clinical medical metal material mainly has pure metal (titanium, tantalum, niobium, zirconium etc.) and stainless steel, cobalt-base alloys
With titanium-base alloy etc..These materials non-degradable in human body, to be permanent implanted, when implant expires in intracorporal be on active service of people
Afterwards, it is necessary to be taken out by second operation, to bring unnecessary physiology pain and financial burden to patient.
Degradable metal be start the beginning of this century rapidly develop using magnesium alloy and iron as the new class medical metal of representative
Material, this kind of new medical metal material have abandoned the tradition that people usually use metal implant as bio-inert material
Thought, and the characteristic of corrosion (degradation) is dexterously easy to happen in human body environment (chloride ion-containing) using magnesium and iron, expect energy
The repair function of metal implant in vivo is realized with controlled manner, and is finally completed reconstruction/function in tissue and repaired it
It is degradable for harmless metal ion and other products afterwards.It degraded slow, and dropped in human body in view of ferrous alloy
Solution product can generate certain toxic side effect to human body, and the research hotspot of research medical degradable metal in recent years is mainly being cured
With on degradable magnesium alloy, such as AZ31, WE43, Mg-Ca, although before magnesium alloy has tempting application as biomaterial
Scape, however study discovery magnesium alloy that there are corrosion rates is too fast, in histoorgan without before sufficiently healing, implantation material is just quickly
Its mechanical integrity can be lost, thus has met clinical demand it is necessary to develop novel degradable alloy.
Zinc is one of the most abundant micronutrient element in human body, and 85% zinc is present in muscle and bone in human body,
11% is present in skin and liver, and remaining zinc is present in tissue everywhere.Normal Zn content (for 24 hours) in serum and urine in human body
It is 800 ± 200 μ g/dL and 109-130 μ g/dL respectively.In multicellular tissue, almost all of zinc is present in into the cell,
30%-40% is present in nucleus, and 50% is present in cytoplasm, remaining to be present in cell membrane in organelle and vesica.It is right
For human body, daily zinc intake is about 15mg/d.Kind of enzymatic is anti-for the structure of numerous macromoleculars and more than 300 for zinc
Crucial effect should be played.Zinc fingers need to be depended on when the substructure and DNA or other albumen qualitative responses of many protein
The rack platform of offer carries out.Zinc ion mainly exists with the composite form with protein and nucleic acid in vivo and participates in each
Kind intermediate supersession, propagation and the expression of gene information, storage and synthesis, meanwhile, also act as stable chromatin and biomembrane knot
The effect of structure.In bone environment, the zinc ion in osteoblast is promoted by activation tRNA synzyme and stimulated gene expression
The synthesis of protein, while also increasing intracellular DNA quantity, to promote osteoblast New born formation and mineralising.Meanwhile zinc from
Son promotes the apoptosis of osteoclast by regulation calcium signal access.Zinc ion is by facilitating bone and inhibiting bone resorption most
Increase bone mass eventually, compared with other microelements, toxicity of the zinc ion in the metabolism of bone is minimum.In painstaking effort pipe ring
In border, cardiac muscle cell can be protected not restored stress damage by Acute oxidative by supplementing zinc ion, while preventing myocardial damage
The inflammatory reaction of initiation.Zinc ion also plays vital effect, the serum of hypertensive patient, lymph in regulating blood pressure
The Zn content of cell and bone can reduce and heart, liver, and Zn content increases in the tissue such as kidney.The experiment in vivo of zinc bracket shows zinc
(6.5 months) are able to suppress local smooth muscle cell proliferation to effectively inhibit endometrial hyperplasia in being chronically implanted.Zinc-deficiency meeting
Cause epidermis, enteron aisle, nervous centralis, immune system, bone and reproductive system generate a series of relevant issues.
Lithium is also the necessary microelement of life, and Environmental Protection in America mechanism was proposed for the adult of a 70kg in 1985
Daily lithium intake is about 650-3100 μ g.The lithium intake of human body about 66%-90% is remaining from vegetables and cereal
Lithium is from animal food.Human body absorbs the soluble salt containing lithium by the sodium-ion channel of small intestine, is discharged, is absorbed by kidney
Lithium ion be evenly distributed in body fluid, it is little with extracellular lithium ion content difference into the cell.Lithium ion is distributed most in cerebellum
It is more, followed by brain and kidney.Lithium in Serum content is directly proportional to the intake of lithium ion, intake 385-1540 μ g/day at
Year human serum lithium content is about 7-28 μ g/L.In identical lithium intake, height and weight are inversely proportional with lithium intake.
Scarce lithium ion normally behaves as exception rather than insanity in mild behavior, scarce lithium ion may with kidney trouble there is also
Relationship.Low concentration lithium agent is suitable for prophylactic treatment, can effectively prevent depressive psychopathia.Supplementing suitable lithium ion can mention
High monoamine oxidase (MAO) activity, stimulation vitamin transport to brain cell, can make one happy, play antidepressant effect.
Since the atomic radius of lithium is small, sodium, potassium, magnesium, calcium plasma can be replaced from the reaction site of biomembrane and enzyme, it can also be with
Aluminium, manganese, vanadium reaction.
The synthesis and performance of document and patent report Zn-Li system alloy not yet both at home and abroad at present, and propose Zn-Li system
Alloy is used as degradable biological medical materials'use.
Summary of the invention
The object of the present invention is to provide a kind of Zn-Li system kirsite and the preparation method and application thereof, zinc prepared by the present invention
Alloy mechanical property is excellent, can provide permanently effective support force in vivo, has excellent cell compatibility, blood compatibility
Property and tissue, organ compatibility, can be used for the preparation of biological and medicinal implant material.
Zn-Li system provided by the invention kirsite, the kirsite include Zn and Li；
By weight percentage, the mass percentage of Li is 0~30% in the kirsite, but does not include 0.
Zn-Li system provided by the invention kirsite is specially following 1) -10) in it is any, with weight percent:
1) it is made of 99.9~99% Zn and 0.1%~1% Li；
2) it is made of 99% Zn and 1% Li；
3) it is made of 99.2% Zn and 0.8% Li；
4) it is made of 99.4% Zn and 0.6% Li；
5) it is made of 99.5% Zn and 0.5% Li；
6) it is made of 99.65% Zn and 0.35% Li；
7) it is made of 99.7% Zn and 0.3% Li；
8) it is made of 99.75% Zn and 0.25% Li；
9) it is made of 99.8% Zn and 0.2% Li；
10) it is made of 99.85% Zn and 0.15% Li；
11) it is made of 99.9% Zn and 0.1% Li.
Further include microelement in the kirsite in above-mentioned kirsite, the microelement be magnesium, calcium, strontium, silicon,
At least one of phosphorus, manganese, silver, copper, tin, iron and rare earth element；
In the kirsite, the mass percentage of the microelement is 0~3%, but does not include 0.
In above-mentioned kirsite, the surface of the kirsite is also coated with coating；
The coating with a thickness of 0.01~5mm；
The coating is that degradable macromolecule coating, ceramic coating, chemical conversion film layer, differential arc oxidation film layer and drug apply
At least one of layer, specifically, the degradable macromolecule coating prepare material be it is following at least one of 1) and 2): 1)
Polycaprolactone, polyglycolic acid, l-polylactic acid, polybutylcyanoacrylate, polyanhydride, poly phosphazene, is gathered to dioxa at polylactic acid
At least one of hexamethylene alkanone, poly- butyric ester and poly- hydroxyl valerate；2) polylactic acid, polycaprolactone, poly- hydroxyl second
The copolymer of at least two compositions in acid, l-polylactic acid, polybutylcyanoacrylate and poly- para-dioxane ketone；It is described can
The molecular weight for preparing material of degraded macromolecular coating is 5000~100000；
The ceramic coating prepare material be hydroxyapatite, it is tricalcium phosphate, four calcium of phosphoric acid oxygen, calcium monohydrogen phosphate, anhydrous
At least one of calcium monohydrogen phosphate, calcium octahate phosphate, fluor-apatite, magnesium hydroxide and strontium phosphide；
The chemical conversion film layer is fluorinated film and/or phosphate film layer, and the material for preparing of the fluorinated film is hydrogen
At least one of fluoric acid, sodium fluoride, potassium fluoride and ammonium fluoride；The material for preparing of the phosphate film layer is dihydric phosphate；
The material for preparing of the differential arc oxidation film layer is that at least one is added in sodium hydroxide and/or potassium hydroxide electrolyte
Following compositions: phosphate, silicate, meta-aluminate, fluoride, zirconates and permanganate；
The medication coat can be anticoagulation medicine, rapamycin and its derivative coating, taxol coating, D actinomycin D
D, at least one in endothelial growth factor, everolimus coating, sirolimus coating, mitomycin coating and antimicrobial coating
Kind, specifically, the anticoagulation medicine is III a receptor antagonist of heparin, hirudin and II b/ of GP.
The present invention also provides a kind of preparation methods of above-mentioned kirsite, include the following steps: (1) by the Zn and institute
Li mixing is stated, mixture is obtained；
(2) by the mixture according to following a) or b) step is handled, and is then cooled down to get the kirsite is arrived；
A) in CO2And SF6Under atmosphere protection, the mixture is subjected to melting or sintering；
B) under vacuum atmosphere protection, hydrogen is dissolved in the mixture and carries out the melting.
In the present invention, in the method, the hydrogen injects the mixture in the case where its air pressure is 1MPa, makes molten metal
Liquid reaches saturation, then pouring into water cooled copper mould cools down alloy liquid from top to bottom；The zinc conjunction obtained under the conditions of this
The porosity 20-30% of gold, 150-200 μm of aperture.
In above-mentioned preparation method, step (1) further includes the steps that the microelement mixing is added.
It further include coating the degradable macromolecule coating, institute after cooling described in step (2) in above-mentioned preparation method
The step of stating ceramic coating, the chemical conversion film layer, the differential arc oxidation film layer or the medication coat.
In the present invention, the method for coating the Biodegradable high-molecular coating is that the kirsite is carried out pickling, so
It is prepared in the colloid that material is dissolved in trichloroethanes preparation 10~30 points of dip-coating in the Biodegradable high molecular coating afterwards
Zhong Hou at the uniform velocity pulls out progress centrifugal treating and obtains the kirsite coated with Biodegradable high-molecular coating, can also use quiet
The preparation of the methods of Electrospun, spin coating；
The method for coating the ceramic coating can be chemical deposition, Biomimetic, sol-gal process, hydrothermal synthesis method
In it is any；
The chemical deposition is to pass through control in the solution containing certain density calcium ion and phosphate anion
Calcium/phosphorus ratio, reaction time, reaction temperature and pH value makes insoluble CaP mineralization in zinc alloy surface.Solution selects Ca
(NO3) 2, Ca-EDTA and CaCl2 etc. provides calcium ion, and K2HPO4, NaH2PO4 and Na3PO4 is selected to provide phosphate anion.It is molten
Liquid chemical reaction temperature general control is between 27~90 DEG C, the time are as follows: 2~for 24 hours, pH value is 5.9~11.9.Acquired coating
Thickness is generally several microns to more than ten microns；
The Biomimetic be kirsite is soaked in temperature be 37 DEG C, the supersaturated calcium microcosmic salt solution of pH=7.4, i.e.,
Certain time in simulated body fluid (balanced salt solution of such as SBF, Hank ' s) generates the process of activity HA coating；
The sol-gal process is: the P2O5 of Ca (NO3) 24H2O and 0.71g of 3.94g is dissolved separately in 10mL's
In ethanol solution.The presoma of calcium is instilled dropwise in the presoma of phosphorus, obtains the calcium phosphorus collosol suspension liquid that Ca/P ratio is 1.67, will
This suspension is placed in closing beaker, and at 26 DEG C, mixing speed is to stir 5h under 400rpm, then uses pulling machine by kirsite
Sample is dipped vertically into certain time in suspension and then lifts out with certain speed, obtains the thickness of film layer according to quasi-, such as
This is lifted for several times repeatedly；Then it places at room temperature and completes ageing treatment for 24 hours, sample is gradually heated to 60 DEG C of holdings later
For 24 hours, 6h finally is sintered at 300 DEG C；
The anodic oxidation and hydrothermal synthesis in conjunction with method be that the kirsite is being contained into 0.01~0.5mol/L β-
In the electrolyte of sodium glycero-phosphate and 0.1~2mol/L calcium acetate, 10~30min is aoxidized at 200~500V, it then will be described
Kirsite handles 1~4h at 200~400 DEG C；
The preparation method for coating fluorinated film in the chemical composition coating is that kirsite is soaked in fluoride ion (hydrogen fluorine
Acid, sodium fluoride, potassium fluoride or ammonium fluoride) solution in be that matrix surface and solution occur chemical reaction and generates MgF2；Phosphate
The preparation method of film layer is soaked in metal containing in phosphatic solution, and chemical reaction Yuan Weisheng occurs for metal and phosphate
At low solubility or insoluble phosphatization salt, generally using dihydric phosphate as the presoma of chemical conversion reaction.
Coat the differential arc oxidation film layer preparation method be will first pass through cerate, laser melting or chemical deposition into
Row pretreatment, then it is to generally use current control in sodium hydroxide/potassium hydroxide electrolyte that kirsite, which is immersed basis,
Direct current, exchange and pulse current may be selected in mode.Pulse frequency can be 10Hz to 2000Hz, and processing is sealed after a certain period of time
Hole and post-processing, usable polymers sealing of hole, self-assembled multilayer film, phosphate and silicate sealing of hole, collosol and gel sealing of hole and layer by layer
Self-assembled film sealing of hole.Post-processing includes hydro-thermal process, high energy pulse electron beam treatment and annealing heat-treatment；
The method for coating the medication coat is physics and chemical method；The physical method coating process is mainly using leaching
Bubble, spraying method；The immersion process is that active medicine and controlled release carrier (or individual active medicine) are configured to solution, is had
Bulk concentration can be different due to solution viscosity drug dose with needed for is different, and then the medical implant is soaked into solution,
Then pass through necessary last handling process, be such as crosslinked, be dry, solidifying and etc., medication coat is made；The spraying method is will
Active medicine and controlled release carrier (or individual active medicine) are configured to solution, then in 0.01~0.50ml/min of flow velocity, surpass
1~10W of acoustical power, 1~50wt.% of concentration of polymer solution utilize Spray painting tool under the process conditions that cycle-index is 10~100 times
Solution is spread evenly across the medical implant surface, through medication coat is made after the post-processing steps such as drying, solidification；
The chemical method is mainly electroplated with electrochemical principle, and the chemical method is carried using active medicine and (or) controlled release
Electro-redox reaction occurs in the electrode by the medical embedded production for body, forms the medical embedded surface stable
By the medication coat being chemically bonded.
In above-mentioned preparation method, the temperature of the melting can be 600~850 DEG C；
The sintering uses element powders mixed-sintering method, prealloy powder sintering process or self-propagating high-temperature synthesis.
In the present invention, the element powders mixed-sintering method is to be uniformly mixed the mixture, is pressed into base, then exists
In vacuum sintering furnace, be warming up to 100~200 DEG C at a slow speed with 2~4 DEG C/min and be followed by rapidly heated to 200 with 30 DEG C/min~
300 DEG C of sintering, then cool down, obtain into the Zn-Li system alloy of porous structure；
The prealloy powder sintering process is that the mixture is carried out high-energy ball milling, type is then pressed into, 250~350
It DEG C carries out heat treatment 10~20 hours, obtains the Zn-Li system alloy of porous structure；
The self-propagating high-temperature synthesis is that the mixture is pressed into base, under inert gas protection, pressure be 1 ×
103~1 × 105Pa, temperature are that Zn-Li system alloy blank is then lighted carry out SHS process at 250~350 DEG C,
Obtain the Zn-Li system alloy of porous structure.
In above-mentioned preparation method, the method also includes being machined the kirsite；
The machining is rolling, forging, quickly at least one of solidification and extruding.
In the present invention, the rolling includes successively carrying out hot rolling and finish rolling, the hot rolling to carry out at 200~300 DEG C,
The finish rolling can carry out at 150~250 DEG C, and the thickness after the kirsite rolling can be 1~2mm；The hot rolling specifically may be used
It is carried out at 260 DEG C, the finish rolling can specifically carry out at 260 DEG C, the concretely 1mm of the thickness after kirsite rolling；
The forging includes the kirsite being carried out to heat preservation under conditions of 150~200 DEG C and at 200~300 DEG C
Under conditions of the step of being forged, the time of the heat preservation is 3~50 hours, and the rate of the forging is not less than 350mm/s；
The quick solidification includes the following steps: in the case where inert atmosphere (argon gas) is protected, using high vacuum fast quenching system system
Standby rapid coagulation band, then the strip is broken into it is powdered, finally under conditions of 150~350 DEG C, vacuum hotpressing 1
~for 24 hours；The high vacuum fast quenching system is provided that 2~8g of feeding quantity, induction heating power are 3~7kW, nozzle and roller
Spacing be 0.80mm, injection pressure be 0.05~0.2MPa, roller speed is 500~3000r/min and nozzle slot having a size of
1film×8mm×6mm；
The temperature of the extruding can be 150~280 DEG C, concretely 260 DEG C；The ingot casting extruding preincubation time can be 0.5
~for 24 hours, and concretely 2h, extrusion ratio can be 10~70, concretely 36, it can be 1mm/s that extrusion speed, which is 0.1~10mm/s,.
Invention further provides the kirsite preparation can application in degraded by body fluid medical implant.
In above-mentioned application, it is described can degraded by body fluid medical implant be degradable blood vessel bracket, the plant of degradable orthopaedics
Enter at least one of object, degradable dental material and degradable suture material.
The invention has the following advantages that
(1) mechanical performance of Zn-Li system prepared by the present invention alloy is excellent, has intensity high, the good feature of plasticity can
Meet physical efficiency bearing position requirement.It can absorb, degrade in vivo again simultaneously, having " regulatable internal corrosion degradation characteristic "
The characteristics of " effective mechanical support is provided ".
It (2) can be injury after implanting when Zn-Li system of the present invention alloy is used for degradable medical implant
Permanently effective medicine support protective effect (such as fixed protection bone tissue or supporting narrow blood vessel) is provided, and can be in chance
It while tissue repair, is gradually absorbed by vivo environment, degradation.Material quantity and volume gradually decrease, the catabolite of material
It can be absorbed by organisms, be metabolized with the ion released, help body recovery and gradually excrete, restore completely in body
Afterwards, material is absorbed degradation completely, is not necessarily to secondary taking-up.
(3) it is provided by the invention can degraded by body fluid medical implant it is nontoxic, have good histocompatbility and blood
Compatibility.
Detailed description of the invention
Fig. 1 is the picture of Zn-Li alloy cast ingot prepared by the embodiment of the present invention 1.
Fig. 2 is the picture of Zn-Li alloy bar material prepared by the embodiment of the present invention 2.
Fig. 3 is the metallograph of Zn-Li alloy bar material prepared by the embodiment of the present invention 2, and wherein Fig. 3 (a) is the gold of pure zinc
Phase picture, Fig. 3 (b) are the metallograph of Zn:0.1Li, and Fig. 3 (c) is the metallograph of Zn:0.4Li, and Fig. 3 (d) is Zn:0.8Li
Metallograph.
Fig. 4 is the X-ray diffraction analysis of Zn-Li alloy prepared by the embodiment of the present invention 2.
Fig. 5 is the photo of the Zn-Li system alloy tensile sample prepared according to testing standard.
Fig. 6 is that the Zn-Li system alloy prepared according to testing standard compresses the photo of sample.
Fig. 7 is the tensile mechanical properties of Zn-Li alloy.
Fig. 8 is the Compressive Mechanical Properties of Zn-Li alloy.
Fig. 9 is the stress strain curve of Zn-Li alloy.
Figure 10 is the compression curve of Zn-Li alloy.
Figure 11 is electrochemical corrosion curve of the Zn-Li alloy in simulated body fluid.
Figure 12 is for Zn-Li alloy to the cell opposite proliferation rate after cytosis different time in 50% leaching liquor.
Figure 13 is for Zn-Li alloy to the cell opposite proliferation rate after cytosis different time in 10% leaching liquor.
Figure 14 is the hemolysis rate of Zn-Li alloy.
Specific embodiment
Experimental method used in following embodiments is conventional method unless otherwise specified.
The materials, reagents and the like used in the following examples is commercially available unless otherwise specified.
Percentage composition as used in the following examples is unless otherwise instructed mass percentage.
Embodiment 1, preparation as cast condition Zn-Li system alloy
Using pure Zn (99.99wt.%), pure Li (99.95wt.%) (being purchased from Huludao Zinc Industry Co., Ltd.) as original
Material, by different mass ratio (mass ratio of Zn and Li are respectively 99:1,99.2:0.8,99.4:0.6,99.5:0.5,99.65:
0.35,99.7:0.3,99.75:0.25,99.8:0.2,99.85:0.15,99.9:0.1) mixing, in CO2+SF6Atmosphere protection
Under, 800 DEG C of meltings, after raw material sufficiently melts, after keeping the temperature 10min, recirculated water is quickly cooled down, and Zn-Li system alloy pig is made (i.e.
Zn-Li system of the present invention kirsite, as shown in Figure 1), wherein Zn-0.1Li indicates that the mass ratio of Zn and Li is 99.9:0.1, Zn-
0.4Li indicates that the mass ratio of Zn and Li is 99.6:0.4, and Zn-0.8Li indicates that the mass ratio of Zn and Li is 99.6:0.8.
Embodiment 2 prepares As-extruded Zn-Li system alloy
The Zn-Li system alloy pig of as cast condition is prepared first, in accordance with the step in the embodiment of the present invention 1, using the side of extruding
Formula prepares Zn-Li system alloy bar material (Zn-Li system kirsite i.e. of the present invention, as shown in Figure 2), using radial compression, ingot casting heat preservation
2h, 260 DEG C of holding temperature, squeezing temperature is 260 DEG C, extrusion ratio 36, and it is 10mm's that extrusion speed 1mm/s, which prepares diameter,
Zn-Li system alloy bar material.
Embodiment 3, the kirsite microscopic examination of Zn-Li system
By the Zn-Li system alloy bar material in the embodiment of the present invention 2, φ 10x1mm sample is prepared by wire cutting, is successively passed through
400#, 800#, 1200# and 2000#SiC sand paper series sanding and polishing.It is ultrasonic respectively in acetone, absolute ethanol and deionized water
It is dry at 25 DEG C after cleaning 15min.Sample is subjected to X-ray diffraction analysis and with after 4% 5~30s of nitric acid alcohol etch sample
It is cleaned with deionized water, after drying, in metallography microscope sem observation.
Fig. 3 is the metallograph of Zn-Li system kirsite, from figure 3, it can be seen that crystal grain is tiny after squeezing, the
Two-phase is evenly distributed on matrix, and Fig. 4 is X ray diffracting spectrum, as seen from Figure 4, is added after Li, pure zinc crystal structure
It changes, increases with Li content, many new diffraction maximums occur, illustrate that Li, which is added, produces significant shadow to the structure of pure zinc
It rings.
Embodiment 4, the kirsite Mechanics Performance Testing of Zn-Li system
The Zn-Li system kirsite that will be prepared according to the method for 1-2 of the embodiment of the present invention, respectively according to ASTM-E8/E8M-09
Extension test standard and the preparation of ASTM-E9 compression standard stretch sample and compression sample (as shown in Figure 5,6), Che Guang.Acetone,
After being cleaned by ultrasonic 15min respectively in dehydrated alcohol and deionized water, drawn at room temperature using universal material mechanics machine
Compression test is stretched, tensile speed and compression speed are respectively 0.05mm/mmmin and 0.005m/mmin.
The room temperature tensile and compression performance such as Fig. 7 of each sample of Zn-Li system kirsite, are compared shown in 8 with pure zinc, Zn-
The excellent combination property of 0.1Li, yield strength 341MPa, tensile strength 431MPa, elongation percentage 28%, compressive strength 788MPa,
It is improved with lithium content, the intensity of alloy further increases, but plasticity declines, and when lithium content reaches 0.8wt.%, material is shown
Brittleness feature.After squeezing, the mechanical property of material is significantly improved.
Fig. 9,10 under Zn-Li system kirsite squeezed state prepared by the present invention stretching and compression curve, can by the figure
Know, with the increase of alloy lithium content, the intensity of material is significantly increased but elongation percentage and compression plasticity are all substantially reduced, when lithium contains
When amount reaches 0.8wt.%, material shows Brittleness, can not measure tensile strength.
Embodiment 5, the test of Zn-Li alloy corrosion performance
By the Zn-Li alloy in the embodiment of the present invention 2 through squeezing, the examination of φ 10x1mm Zn-Li alloy is prepared by wire cutting
Print, successively through 400#, 800#, 1200# and 2000#SiC sand paper series sanding and polishing.In acetone, dehydrated alcohol and deionization
It is dry at 25 DEG C after being cleaned by ultrasonic 15min respectively in water.Electro-chemical test is carried out later, and electro-chemical test is by above-mentioned processing
Good sample carries out electro-chemical test in Hank ' s simulated body fluid by Autolab electrochemical workstation.(Hank ' s simulation
Body fluid NaCl 8.0g, CaCl2 0.14g,KCl 0.4g,NaHCO30.35g, glucose 1.0g, MgCl2·6H2O 0.1g,
Na2HPO4·2H2O 0.06g,KH2PO4 0.06g,MgSO4·7H2O0.06g is dissolved in 1L deionized water)
Figure 11 is the anodic polarization curves of pure zinc and Zn-Li alloy in Hank ' s simulated body fluid, can from Figure 11
Out, after Li is added, the corrosion potential of material is negative to be moved, and corrosion rate is obviously accelerated, by the way that pure zinc, Zn- is calculated
The degradation speed of 0.1Li, Zn-0.8Li are 0.027mm/year, 0.038mm/year, 0.629mm/year respectively.
The cell compatibility experiment of embodiment 6, Zn-Li alloy
By Zn-Li alloy prepared by the method for the embodiment of the present invention 2, φ 10x1mm coupons, warp are prepared by wire cutting
400#, 800#, 1200# and 2000#SiC sand paper series sanding and polishing.It is ultrasonic respectively in acetone, absolute ethanol and deionized water
It is dry at 25 DEG C after cleaning 15min.Contact angle test is carried out to sample by deionized water, sample through ultraviolet-ray sterilizing,
Be placed in sterile orifice plate, by specimen surface product with containing 10% serum and 1% dual anti-(penicillin adds streptomysin mixed solution)
DMEM cell culture medium is 1.25cm by the ratio between volume2DMEM cell culture medium is added in the ratio of/mL, is placed in 37 DEG C, 95% phase
To humidity, 5%CO2In incubator for 24 hours, Zn-Li alloy leaching liquor stoste is obtained, leaching liquor stoste is diluted to concentration respectively is
50%, 10% dilution leaching liquor seals, and 4 DEG C of refrigerators save backup.
Dilution leaching liquor and cell inoculation culture and result are observed: after HUVEC cell recovery, passage, being suspended in DMEM
It in cell culture medium, is inoculated on 96 well culture plates, after culture 24 hours, DMEM cell culture medium, sun is added in negative control group
Property control group the cell culture medium containing 10%DMSO is added, experimental group is added Zn-Li alloy obtained above and dilutes leaching liquor, makes
Final cell concentration is 2~5 × 104/mL.It is placed in 37 DEG C, 5%CO2It is cultivated in incubator, takes out culture after 1,2,4 day respectively
Plate observes the form of living cells under inverted phase contrast microscope and carries out the test of cell survival rate by CCK8 kit.
Figure 12,13 are relative survival rate of the HUVEC cell in 50%, 10%Zn-Li alloy leaching liquor respectively, from figure
12, it can be seen that pure zinc and Zn-0.1Li alloy have overt toxicity function cells to deposit in cell in 50% leaching liquor group in 13
Motility rate is lower than 70%.When Li content is 0.8, material is to cytotoxic.And 10% leaching liquor group, cell survival rate are more than
Negative control group has excellent cell compatibility.In vivo in environment, due to body fluid circulatory, dropped caused by material degradation
Solution product can be diluted by body fluid, so more reasonable using dilution leaching liquor assessment cell compatibility.It is found by cell experiment,
Zn-Li alloy has good biocompatibility.
Embodiment 7, the test of Zn-Li alloy blood compatibility
Zn-Li alloy by the embodiment of the present invention 2 through rolling prepares φ 10x1mm Zn-Li alloy sample by wire cutting
Piece, through 400#, 800#, 1200# and 2000#SiC sand paper series sanding and polishing.Divide in acetone, absolute ethanol and deionized water
It Chao Shengqingxi not be dry at 25 DEG C after 15min.New blood with healthy volunteer is acquired, is placed in and includes 3.8wt.% lemon
Sour sodium is saved as the anticoagulant tube of anti-coagulants.Dilute blood sample is made by the dilution proportion of 4:5 with 0.9% physiological saline.It will
Sample is immersed in 10mL physiological saline, and 0.2mL dilute blood sample, 37 ± 0.5 DEG C of heat preservations are added in 37 ± 0.5 DEG C of heat preservation 30min
60min.Using 10mL physiological saline as negative control group, 10mL deionized water is as positive controls.It is centrifuged through 3000rpm
5 minutes, supernatant Unic-7200 ultraviolet-uisible spectrophotometer 545nm is taken to measure absorbance OD value, three groups of Duplicate Samples are set
To carry out statistical analysis.
Hemolysis rate is calculated with following formula:
Hemolysis rate=(experimental group OD value-feminine gender organizes OD value)/(positive group OD value-feminine gender organizes OD value) × 100%.
Experimental result such as Figure 14, the hemolysis rate of Zn-Li alloy of the present invention are below 1%, far smaller than clinical use requirement
Secure threshold 5%, Zn-Li system of the present invention kirsite shows good blood compatibility.
Claims (8)
1. a kind of Zn-Li system kirsite, it is characterised in that: the kirsite is made of Zn and Li；
By weight percentage, the mass percentage of Li is 0.1% ~ 1% in the kirsite；
The surface of the kirsite is also coated with coating；
The coating with a thickness of 0.01 ~ 5mm；
The coating is in degradable macromolecule coating, ceramic coating, chemical conversion film layer, differential arc oxidation film layer and medication coat
At least one；
The degradable macromolecule coating prepare material be it is following at least one of 1) and 2): 1) polycaprolactone, polylactic acid,
Polyglycolic acid, polybutylcyanoacrylate, polyanhydride, poly phosphazene, poly- para-dioxane ketone, poly- butyric ester and poly-
At least one of hydroxyl valerate；2) polylactic acid, polycaprolactone, polyglycolic acid, polybutylcyanoacrylate and poly- to two
The copolymer of at least two compositions in oxinane ketone；The molecular weight for preparing material of the degradable macromolecule coating is
5000~100000；
The material for preparing of the ceramic coating is hydroxyapatite, tricalcium phosphate, four calcium of phosphoric acid oxygen, calcium monohydrogen phosphate, anhydrous phosphoric acid
At least one of hydrogen calcium, calcium octahate phosphate, fluor-apatite, magnesium hydroxide and strontium phosphide；
The chemical conversion film layer is fluorinated film and/or phosphate film layer；The fluorinated film prepare material be hydrofluoric acid,
At least one of sodium fluoride, potassium fluoride and ammonium fluoride；The material for preparing of the phosphate film layer is dihydric phosphate；
The material for preparing of the differential arc oxidation film layer is that addition is at least one following in sodium hydroxide and/or potassium hydroxide electrolyte
Ingredient: phosphate, silicate, meta-aluminate, fluoride, zirconates and permanganate；
The medication coat is anticoagulation medicine, rapamycin and its derivative coating, taxol coating, actinomycin D, endothelium
At least one of Porcine HGF, everolimus coating, sirolimus coating, mitomycin coating and antimicrobial coating.
2. kirsite according to claim 1, it is characterised in that: the anticoagulation medicine is heparin, hirudin and GP
II b/, III a receptor antagonist.
3. kirsite according to claim 1, it is characterised in that: the polylactic acid is l-polylactic acid.
4. the preparation method of kirsite of any of claims 1-3 includes the following steps: (1) by the Zn and institute
Li mixing is stated, mixture is obtained；
(2) by the mixture according to following a) or b) step is handled, and is then cooled down to get the kirsite is arrived；
A) in CO2And SF6Under atmosphere protection, the mixture is subjected to melting or sintering；
B) under vacuum atmosphere protection, hydrogen is dissolved in the mixture and carries out the melting；
It further include coating the degradable macromolecule coating, the ceramics painting in the method, after cooling described in step (2)
The step of layer, the chemical conversion film layer, the differential arc oxidation film layer or medication coat.
5. the preparation method according to claim 4, it is characterised in that: the temperature of the melting is 600 ~ 850 DEG C；
The sintering uses element powders mixed-sintering method, prealloy powder sintering process or self-propagating high-temperature synthesis.
6. preparation method according to claim 4 or 5, it is characterised in that: the method also includes by the kirsite into
The step of row machining；
The machining is rolling, forging, quickly at least one of solidification and extruding.
7. kirsite described in any one of claim 1-3 can application in degraded by body fluid medical implant in preparation.
8. application according to claim 7, it is characterised in that: it is described can degraded by body fluid medical implant be degradable blood vessel
At least one of bracket, degradable orthopaedics implantation material, degradable dental material and degradable suture material.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610387456.7A CN107460371B (en) | 2016-06-02 | 2016-06-02 | A kind of Zn-Li system kirsite and the preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610387456.7A CN107460371B (en) | 2016-06-02 | 2016-06-02 | A kind of Zn-Li system kirsite and the preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107460371A CN107460371A (en) | 2017-12-12 |
| CN107460371B true CN107460371B (en) | 2019-01-22 |
Family
ID=60545575
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610387456.7A Active CN107460371B (en) | 2016-06-02 | 2016-06-02 | A kind of Zn-Li system kirsite and the preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107460371B (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106282664A (en) * | 2016-08-25 | 2017-01-04 | 上海交通大学 | Biodegradable medical zinc lithium binary alloy material and preparation method and application |
| CN106319287A (en) * | 2016-08-25 | 2017-01-11 | 上海交通大学 | Biodegradable medical Zn-Li-X series alloy material and preparation method and application |
| CN108048690B (en) * | 2017-11-28 | 2019-08-13 | 中国科学院宁波工业技术研究院慈溪生物医学工程研究所 | A kind of zinc-containing alloy of controllable degradation rate and application |
| CN108396176A (en) * | 2018-01-24 | 2018-08-14 | 烟台南山学院 | A kind of medical degradable zinc alloy flakes of Guided Bone Regeneration and preparation method thereof |
| CN108315583B (en) * | 2018-03-23 | 2021-09-28 | 北京大学 | Zn-Li-Mn zinc alloy and preparation method and application thereof |
| CN108277386A (en) * | 2018-03-23 | 2018-07-13 | 北京大学 | A kind of Zn-Li-Mg systems kirsite and the preparation method and application thereof |
| CN109432514B (en) * | 2018-12-12 | 2021-12-21 | 西南大学 | Degradable magnesium alloy bone nail with scaly bone-imitating nano-structure coating and preparation method thereof |
| CN110241453A (en) * | 2019-04-25 | 2019-09-17 | 西南大学 | A kind of release fluoride and the degradable kirsite bone nail of cerium and preparation method thereof |
| CN110585475A (en) * | 2019-09-18 | 2019-12-20 | 西南大学 | Light-operated antibacterial degradable zinc alloy suture material and preparation method thereof |
| CN110512117B (en) * | 2019-09-27 | 2022-05-13 | 石家庄新日锌业有限公司 | Medical zinc alloy material and preparation method thereof |
| CN111334688B (en) * | 2020-02-17 | 2022-10-21 | 北京大学 | Zn-RE series zinc alloy and preparation method and application thereof |
| CN113005330A (en) * | 2021-03-17 | 2021-06-22 | 昆明理工大学 | Biodegradable superfine crystal Zn-Li alloy material and preparation method and application thereof |
| CN113289071B (en) * | 2021-05-18 | 2022-06-28 | 中国科学院宁波材料技术与工程研究所 | Implantable zinc-based alloy surface structure and preparation method and application thereof |
| CN113637861B (en) * | 2021-08-13 | 2022-05-27 | 湘潭大学 | Zn-Se alloy and preparation method and application thereof |
| CN114748686B (en) * | 2022-04-18 | 2023-02-03 | 北京大学 | Personalized zinc alloy bone implant and preparation method and application thereof |
| CN115181874B (en) * | 2022-08-04 | 2023-03-31 | 北京科技大学 | Method for generating carbonate protective layer on surface of zinc alloy and application thereof |
| CN115874084B (en) * | 2022-12-23 | 2024-02-06 | 北京大学 | Zn-Li creep-resistant zinc alloy and preparation method and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101748313A (en) * | 2008-12-19 | 2010-06-23 | 北京有色金属与稀土应用研究所 | Zinc-lithium alloy material and preparation method thereof |
| CN104212998A (en) * | 2014-08-21 | 2014-12-17 | 北京大学 | Zn-Mg zinc alloy and preparation method and application thereof |
| CN104651665A (en) * | 2015-03-13 | 2015-05-27 | 周功耀 | Corrosion-resistant and high-strength and toughness Zn-Fe-Li-based zinc alloy capable of being degraded in human body and application of corrosion-resistant and high-strength and toughness Zn-Fe-Li-based zinc alloy |
| CN105925847A (en) * | 2016-05-12 | 2016-09-07 | 管仁国 | Novel biodegradable zinc-based metal material and ureteral expandable stent obtained through material |
-
2016
- 2016-06-02 CN CN201610387456.7A patent/CN107460371B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101748313A (en) * | 2008-12-19 | 2010-06-23 | 北京有色金属与稀土应用研究所 | Zinc-lithium alloy material and preparation method thereof |
| CN104212998A (en) * | 2014-08-21 | 2014-12-17 | 北京大学 | Zn-Mg zinc alloy and preparation method and application thereof |
| CN104651665A (en) * | 2015-03-13 | 2015-05-27 | 周功耀 | Corrosion-resistant and high-strength and toughness Zn-Fe-Li-based zinc alloy capable of being degraded in human body and application of corrosion-resistant and high-strength and toughness Zn-Fe-Li-based zinc alloy |
| CN105925847A (en) * | 2016-05-12 | 2016-09-07 | 管仁国 | Novel biodegradable zinc-based metal material and ureteral expandable stent obtained through material |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107460371A (en) | 2017-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107460371B (en) | A kind of Zn-Li system kirsite and the preparation method and application thereof | |
| CN107460372B (en) | A kind of Zn-Mn system kirsite and the preparation method and application thereof | |
| CN104212998B (en) | Zn-Mg zinc alloy and preparation method and application thereof | |
| Jia et al. | In vitro and in vivo studies of Zn-Mn biodegradable metals designed for orthopedic applications | |
| US11590266B2 (en) | Biodegradable iron-containing compositions, methods of preparing and applications therefor | |
| JP6431957B2 (en) | Biodegradable metal alloy | |
| CN107456610B (en) | Zn-Ag series zinc alloy and preparation method and application thereof | |
| CN104195368B (en) | A kind of Zn-Sr system kirsite and preparation method and application | |
| CN104195369B (en) | A kind of Zn-Ca system kirsite and preparation method and application | |
| CN107456601B (en) | Zn-Cu series zinc alloy and preparation method and application thereof | |
| CN104911427B (en) | A kind of Mg Ca Sr Zn systems magnesium alloy and preparation method and application | |
| CN102552973A (en) | Medical degradable and absorbable Mg-Sr-Ca series magnesium alloy implant and preparation method thereof | |
| CN108315583B (en) | Zn-Li-Mn zinc alloy and preparation method and application thereof | |
| CN102580143A (en) | Medical degradable and absorbable Mg-Sr system magnesium alloy implant and preparation method thereof | |
| He et al. | Review on magnesium and magnesium-based alloys as biomaterials for bone immobilization | |
| CN108277386A (en) | A kind of Zn-Li-Mg systems kirsite and the preparation method and application thereof | |
| Pan et al. | Improvement of corrosion and biological properties of microarc oxidized coatings on Mg–Zn–Zr alloy by optimizing negative power density parameters | |
| CN106606801B (en) | A kind of Zn-ZnO system kirsite and the preparation method and application thereof | |
| CN102978495A (en) | Mg-Sr-Zn alloy and preparation method thereof | |
| CN106606800B (en) | A kind of Zn-Fe system kirsite and the preparation method and application thereof | |
| Niu et al. | The effects of Cu and Mn on the microstructure, mechanical, corrosion properties and biocompatibility of Zn–4Ag alloy | |
| CN113106295A (en) | Degradable biomedical material Zn-Si-X series zinc alloy and preparation method thereof | |
| Su et al. | Blending with transition metals improves bioresorbable zinc as better medical implants | |
| CN106606806B (en) | A kind of Zn-Mg1Ca system kirsite and the preparation method and application thereof | |
| CN111676390B (en) | Zn-Ga alloy, preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |